Literature DB >> 17657592

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.

Jennifer Fiegel1, Lucila Garcia-Contreras, Matthew Thomas, Jarod VerBerkmoes, Katharina Elbert, Anthony Hickey, David Edwards.   

Abstract

PURPOSE: To develop an aerosol system for efficient local lung delivery of a tuberculostatic drug.
METHODS: The antibiotic, capreomycin sulfate, was spray dried to form a dry powder aerosol. The chemical content and physical properties of resulting particles were assessed under various storage conditions. Plasma concentrations of capreomycin after insufflation into guinea pigs were evaluated at three doses, and compared to IV and IM administration of a capreomycin solution.
RESULTS: Dry powder aerosols containing capreomycin were formulated to enable efficient delivery of large drug masses to the lungs of guinea pigs. Aerosols loaded with 73% CS were shown to possess good aerosolization properties and physical-chemical stability for up to 3 months at room temperature. Upon insufflation into guinea pigs, the amount of CS reaching the bloodstream was significantly lower compared to IV or IM administration, but resulted in a significantly longer drug half-life.
CONCLUSIONS: The results indicate that large doses of capreomycin in dry powder form can be efficiently delivered to the lungs of guinea pigs, which may result in high local drug exposure but significantly reduced systemic exposure as suggested by plasma concentrations in the present studies. These systems have considerable potential to provide more effective therapy for MDR-TB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17657592     DOI: 10.1007/s11095-007-9381-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  The influence of formulation components on the aerosolisation properties of spray-dried powders.

Authors:  Naumana R Rabbani; Peter C Seville
Journal:  J Control Release       Date:  2005-10-13       Impact factor: 9.776

2.  Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload.

Authors:  Bijay Kumar Padhi; Mahavir B Chougule; Ambikanandan Misra
Journal:  Pharm Dev Technol       Date:  2006       Impact factor: 3.133

3.  Aerosolized antibiotics in cystic fibrosis.

Authors:  William P Sexauer; Stanley B Fiel
Journal:  Semin Respir Crit Care Med       Date:  2003-12       Impact factor: 3.119

4.  A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

Authors:  J Eisenberg; M Pepe; J Williams-Warren; M Vasiliev; A B Montgomery; A L Smith; B W Ramsey
Journal:  Chest       Date:  1997-04       Impact factor: 9.410

5.  A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia.

Authors:  B Hirschel; A Lazzarin; P Chopard; M Opravil; H J Furrer; S Rüttimann; P Vernazza; J P Chave; F Ancarani; V Gabriel
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

6.  Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis.

Authors:  L V Sacks; S Pendle; D Orlovic; M Andre; M Popara; G Moore; L Thonell; S Hurwitz
Journal:  Clin Infect Dis       Date:  2000-12-12       Impact factor: 9.079

7.  Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.

Authors:  Gabrielle Pilcer; Thami Sebti; Karim Amighi
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

8.  Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis.

Authors:  Sonya Shin; Jennifer Furin; Félix Alcántara; Anne Hyson; Keith Joseph; Epifanio Sánchez; Michael Rich
Journal:  Chest       Date:  2004-03       Impact factor: 9.410

9.  Aerosolization properties, surface composition and physical state of spray-dried protein powders.

Authors:  Cynthia Bosquillon; Paul G Rouxhet; François Ahimou; Denis Simon; Christine Culot; Véronique Préat; Rita Vanbever
Journal:  J Control Release       Date:  2004-10-19       Impact factor: 9.776

10.  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial.

Authors:  G S Leoung; D W Feigal; A B Montgomery; K Corkery; L Wardlaw; M Adams; D Busch; S Gordon; M A Jacobson; P A Volberding
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

View more
  23 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

3.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

4.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

Review 5.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

6.  A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy.

Authors:  Ragan A Pitner; Phillip G Durham; Ian E Stewart; Steven G Reed; Gail H Cassell; Anthony J Hickey; Darrick Carter
Journal:  J Pharm Sci       Date:  2019-05-29       Impact factor: 3.534

7.  Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.

Authors:  Nashwa El-Gendy; Kristin L Aillon; Cory Berkland
Journal:  Int J Pharm       Date:  2010-03-07       Impact factor: 5.875

8.  Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.

Authors:  S Sommerfeld Ross; S Gharse; L Sanchez; J Fiegel
Journal:  Int J Pharm       Date:  2017-08-04       Impact factor: 5.875

9.  Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.

Authors:  Lucila Garcia-Contreras; Jean C Sung; Pavan Muttil; Danielle Padilla; Martin Telko; Jarod L Verberkmoes; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

10.  Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis.

Authors:  Ashwin S Dharmadhikari; Mohan Kabadi; Bob Gerety; Anthony J Hickey; P Bernard Fourie; Edward Nardell
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.